The FDA announced today that is has completed review of reports of suicidal behavior from its clinical studies of 11 drugs used to treat epilepsy, psychiatric disorders and other conditions. In the Agencies investigation patients using the following antiepileptic drugs had twice the risk of suicidal behavior than those taking placebo:

Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, Tegretol XR)
Felbamate (marketed as Felbatol)
Gabapentin (marketed as Neurontin)
Lamotrigine (marketed as Lamictal)
Levetiracetam (marketed as Keppra)
Oxcarbazepine (marketed as Trileptal)
Pregabalin (marketed as Lyrica)
Tiagabine (marketed as Gabitril)
Topiramate (marketed as Topamax)
Valproate (marketed as Depakote, Depakote ER, Depakene, Depacon)
Zonisamide (marketed as Zonegran)

The FDA further alerted healthcare professionals to closely monitor their patients using any antiepileptic drugs for behavioral changes that could result in suicidal thoughts, actions, behaviors or depression. The FDA expects that label changes to these drugs will occur in a broad based manner.

If you have lost a loved one to suicide due to use any of the antiepileptic drugs listed and would like to learn your legal rights, please contact us 1-888-775-3779. Our law firm is presently investigating claims involving antiepileptic drugs and suicide.

Defective Drugs, FDA